Funding for Cell and Gene Therapies Exceeded 70 Billion Last Year: Kalorama Report

Total funding from all sources for cell and gene therapy companies totaled  $70.8 billion last year, according to a compilation of deals performed by Kalorama Information as part of its recent report.  The growth in money being injected into cell and gene therapy companies continues to grow in 2022, according to the firm’s report: Cell […]

Cardiovascular Disease Pumps Sales of Cardiac Markers to $2,517 Million

“With the incidence of cardiovascular disease escalating, cardiac markers are in huge demand and a constant subject of research for improvement.” – Kalorama Information Despite improvements in treatment and increased public awareness about prevention, cardiovascular disease (CVD) is still the leading cause of death worldwide. CVD causes half of all deaths in several developed countries […]

10 Recent Developments in Cell and Gene Therapy

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Intellia Therapeutics, based in Cambridge, MA, has acquired Berkeley, CA-based Rewrite Therapeutics, a private biotech company specializing in developing novel genome editing technologies. Rewrite’s Rewriter platform utilizes CRISPR-guided DNA polymerases […]

Infographic: Blood Screening & Blood Transfusions

“The United States is the biggest user of blood transfusions—approximately 5 million people in the U.S. receive blood and blood components through 10.9 million transfusions per year.” – Kalorama Information   The global $2.5 billion blood screening market is evolving on many levels, and despite it’s maturity the industry is poised for growth through 2026 […]

Coagulation Tests Near 4 Billion, Per IVD Newsletter

The 2021 global market for coagulation tests (lab-based and all POC) neared 4 billion last year.    PT and d-dimer tests lead revenues, per Kalorama’s In Vitro Diagnostic Business Outlook.  The publication focuses on one aspect of the IVD market in each issue. The publication comes out 2 times a month.  This issue focused on […]

8 Recent Developments in Cell and Gene Therapy

There have been a number of recent developments in cell and gene therapy, as detailed in our bi monthly newsletter, Cell and Gene Therapy Business Outlook.  New approvals in various countries, and technology licenses. Bristol-Myers Squibb K.K., a Tokyo-based subsidiary of Bristol-Myers Squibb (BMS), has announced that Japan’s Ministry of Health, Labour and Welfare has […]

Digital Pathology Gets Big

The global digital pathology market is valued at $866 million in 2021, consisting of hardware, software and related services for clinical applications. In 2020, markets experienced slowing demand early in the year due to reduced orders and budget freezes as the COVID-19 pandemic surged on over the year. The impact began to soften in the […]

Viral Vectors Market Reaches $712 Million as Gene Therapy and COVID-19 Vaccines Create Growth

  The total viral vector market sported revenues of $712.2 million in 2021, according to research published in Viral Vectors Market for Cell Therapy Market: Analysis and Opportunities, a new report by leading medical market researcher Kalorama Information. Viral vectors are altered viruses that can safely transport therapeutic products into cells and growth is forecast […]

This Week in Cell and Gene Therapy: 12 Recent Developments

The following are a dozen developments in the cell and gene therapy market from Volume 1, Issue 14 of Cell and Gene Therapy Business Outlook, published January 10, 2022.   Allogene Therapeutics, based South San Francisco, CA, has announced that the Food and Drug Administration has cleared the company to resume clinical trials its CAR-T […]

Global Liquid Biopsy Market to Exceed $3 Billion by 2026 with Focus on Cancer and Oncology

  There are over 40 companies active in the $1 billion global market for liquid biopsy diagnostics and monitoring tests. And demand is growing swiftly, at a projected compound annual growth rate (CAGR) of 29.5% over the next five years, as patients, clinicians, and payors increasingly accept liquid biopsy as an alternative or complementary procedure […]